These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8097540)

  • 1. Structure-activity relationships in the trans-hexahydroindolo[4,3-ab]phenanthridine ("benzergoline") series. 2. Resolution, absolute configuration, and dopaminergic activity of the selective D1 agonist CY 208-243 and its implication for an "extended rotamer-based dopamine receptor model".
    Seiler MP; Floersheim P; Markstein R; Widmer A
    J Med Chem; 1993 Apr; 36(8):977-84. PubMed ID: 8097540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. trans-hexahydroindolo[4,3-ab]phenanthridines ("benzergolines"), the first structural class of potent and selective dopamine D1 receptor agonists lacking a catechol group.
    Seiler MP; Hagenbach A; Wüthrich HJ; Markstein R
    J Med Chem; 1991 Jan; 34(1):303-7. PubMed ID: 1671417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist.
    Knoerzer TA; Nichols DE; Brewster WK; Watts VJ; Mottola D; Mailman RB
    J Med Chem; 1994 Jul; 37(15):2453-60. PubMed ID: 7914538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist.
    Brewster WK; Nichols DE; Riggs RM; Mottola DM; Lovenberg TW; Lewis MH; Mailman RB
    J Med Chem; 1990 Jun; 33(6):1756-64. PubMed ID: 1971308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine receptor ligands.
    Brewster WK; Nichols DE; Watts VJ; Riggs RM; Mottola D; Mailman RB
    J Med Chem; 1995 Jan; 38(2):318-27. PubMed ID: 7830274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors.
    Knoerzer TA; Watts VJ; Nichols DE; Mailman RB
    J Med Chem; 1995 Aug; 38(16):3062-70. PubMed ID: 7636869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of dopamine receptor subtypes by comparative structure-activity relationships: dopaminomimetic activities and solid state conformation of monohydroxy-1,2,3,4,4a,5,10,10a-octahydrobenz[g]quinolines and its implications for a rotamer-based dopamine receptor model.
    Seiler MP; Markstein R; Walkinshaw MD; Boelsterli JJ
    Mol Pharmacol; 1989 May; 35(5):643-51. PubMed ID: 2566903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist.
    Mottola DM; Brewster WK; Cook LL; Nichols DE; Mailman RB
    J Pharmacol Exp Ther; 1992 Jul; 262(1):383-93. PubMed ID: 1352553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Centrally acting serotonergic and dopaminergic agents. 1. Synthesis and structure-activity relationships of 2,3,3a,4,5,9b-hexahydro-1H-benz[e]indole derivatives.
    Lin CH; Haadsma-Svensson SR; Lahti RA; McCall RB; Piercey MF; Schreur PJ; Von Voigtlander PF; Smith MW; Chidester CG
    J Med Chem; 1993 Apr; 36(8):1053-68. PubMed ID: 8097537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further definition of the D1 dopamine receptor pharmacophore: synthesis of trans-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphth[2,1-b]azepines as rigid analogues of beta-phenyldopamine.
    Negash K; Nichols DE; Watts VJ; Mailman RB
    J Med Chem; 1997 Jul; 40(14):2140-7. PubMed ID: 9216832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.
    Lin CH; Haadsma-Svensson SR; Phillips G; Lahti RA; McCall RB; Piercey MF; Schreur PJ; Von Voigtlander PF; Smith MW; Chidester CG
    J Med Chem; 1993 Apr; 36(8):1069-83. PubMed ID: 8097538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic and persistent interaction between the D2 agonist, bromocriptine, and the D1 selective agonist, CY 208-243.
    Robertson HA; Peterson MR; Worth GG
    Brain Res; 1992 Oct; 593(2):332-4. PubMed ID: 1360321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys.
    Luquin MR; Guillén J; Martínez-Vila E; Laguna J; Martínez-Lage JM
    Eur J Pharmacol; 1994 Mar; 253(3):215-24. PubMed ID: 7911084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys.
    Rosenzweig-Lipson S; Bergman J
    J Pharmacol Exp Ther; 1993 Nov; 267(2):765-75. PubMed ID: 7902432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.
    Cueva JP; Giorgioni G; Grubbs RA; Chemel BR; Watts VJ; Nichols DE
    J Med Chem; 2006 Nov; 49(23):6848-57. PubMed ID: 17154515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of continuous exposure to selective D1 and D2 dopaminergic agonists on rotational behavior in supersensitive mice.
    Winkler JD; Weiss B
    J Pharmacol Exp Ther; 1989 May; 249(2):507-16. PubMed ID: 2566677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydrexidine: a new potent peripheral dopamine D1 receptor agonist.
    Kohli JD; Horn PT; Glock D; Brewster WK; Nichols DE
    Eur J Pharmacol; 1993 Apr; 235(1):31-5. PubMed ID: 8100195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents.
    Watts VJ; Lawler CP; Gilmore JH; Southerland SB; Nichols DE; Mailman RB
    Eur J Pharmacol; 1993 Sep; 242(2):165-72. PubMed ID: 7902811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist.
    Smith HP; Nichols DE; Mailman RB; Lawler CP
    Eur J Pharmacol; 1997 Mar; 323(1):27-36. PubMed ID: 9105873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping.
    Mottola DM; Laiter S; Watts VJ; Tropsha A; Wyrick SD; Nichols DE; Mailman RB
    J Med Chem; 1996 Jan; 39(1):285-96. PubMed ID: 8568818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.